Financial Performance - The net loss attributable to common stockholders for Q4 2025 was $79.7 million, compared to $64.9 million in the prior-year period[11]. - For the full year 2025, the net loss attributable to common stockholders was $333.6 million, up from $243.8 million in 2024[11]. - Total operating expenses for 2025 were $338.9 million, compared to $260.3 million in 2024[18]. Funding and Cash Position - Eikon raised $381 million in gross proceeds from an upsized IPO in February 2026, strengthening its balance sheet[4]. - As of December 31, 2025, Eikon had cash, cash equivalents, and marketable securities of $336 million, expected to fund operations into the second half of 2027[7]. - Eikon's total assets as of December 31, 2025, were $594.7 million, an increase from $491.2 million in 2024[20]. Research and Development - R&D expenses for Q4 2025 were $65.2 million, a 21% increase from $53.9 million in Q4 2024, primarily due to accelerated clinical trial activity[8]. - For the full year 2025, R&D expenses totaled $250.3 million, up 22% from $204.5 million in 2024, driven by expanded clinical trials and increased facility costs[8]. - Eikon completed enrollment in the TeLuRide-005 Phase 2 trial for EIK1001 in first-line treatment of stage 4 non-small cell lung cancer, with data expected in 2H 2026[4]. General and Administrative Expenses - G&A expenses for Q4 2025 were $17.9 million, a 29% increase from $13.9 million in Q4 2024, mainly due to higher compensation costs[10].
Eikon Therapeutics(EIKN) - 2025 Q4 - Annual Results